You are here
Grifols acquires 44% of GigaGen for 35 million dollars
Grifols, member of CataloniaBio, reached an agreement to acquire a 44% stake in GigaGen Inc., for 35 million dollars in cash. GigaGen is a biopharmaceutical company based in San Francisco (California) specialized in the discovery and development of pre-clinical biotherapeutics.
GigaGen currently has several projects under way in collaboration with various pharmaceutical companies. The company also heads a range of in-house research projects, including the development of world's first recombinant intravenous immunoglobulin and a diverse portfolio of immuno-oncology therapies.
This transaction allows Grifols to further strengthen its R&D+i portfolio by acquiring holdings in research projects and companies that complement its activity and hold the potential of generating high added value.
Photo: GigaGen Inc